Treatment
The treatment option in this study is mirvetuximab + carboplatin followed by mirvetuximab in maintenance therapy.
Mirvetuximab is given intravenously every 3 weeks.
Treatment duration
The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.
Contact
To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.